Bristol Myers Squibb (NYSE: BMY; BMS) delivered some good news to investors in reporting fourth-quarter and full-year 2025 results on Thursday. The pharma giant beat analyst consensus forecasts by ...

Sometimes it takes a combination of building pressures to spark a landslide of positive change. For pharmaceutical giant Bristol Myers Squibb (BMS), the moment came following its $74 billion ...

SIM swapping has become so widespread that lawmakers now consider it a national security threat. And no one is immune – not even high-profile figures like Twitter and Bluesky founder Jack Dorsey, or ...

As smartphones have become more pervasive in our lives, we've all kind of been forced to pick up basic knowledge and terminology over the years. Where previously certain jargon would exclusively be ...

Nearly 4,500 Tesla Model 3 and Model Y owners in South Korea have complained about battery malfunctions that prevent charging. The problem, which primarily affects 2021 models, has drawn the scrutiny ...

Federal agents with Homeland Security Investigations discovered an additional 200,000 SIM cards at a location in New Jersey, law enforcement sources confirmed to CBS News. Agents were first tipped off ...

Whether you've recently added a new line to your Android phone for faster internet or gotten a new work SIM, a "SIM Not Provisioned" error message can disrupt your ...

The recent discovery of a sprawling SIM farm operation in the New York City area has revealed how these facilities, typically used by cybercriminals to flood phones with spam calls and texts, have ...

Beecher Manufacturing Services acquired BMS Manufacturing Co. in Watkins Glen, New York. The acquisition will help Ward Apparatus, another Beecher company, increase fire truck production. The ...

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...